In retrospect years later, this will be the time point to be remembered in cancer therapy, to which countless manpower, time and resources have been devoted.

“Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL”

 

---